## DEPARTMENT OF HEALTH & HUMAN SERVICES



M33071

Food and Drug Administration Denver District Office Building 20 – Denver Federal Center P.O. Box 25087 Denver, Colorado 80225-0087 TELEPHONE: 303-236-3000

January 24, 2000

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

## **WARNING LETTER**

Mr. Larry Wooton Owner / Manager Roswell Livestock Auction Co. 900 N. Garden Roswell, NM 88202

Ref. #. - DEN-00-13

**PURGED** 

Dear Mr. Wooton,

An investigation of your livestock auction operations, located at 900 N. Garden, Roswell, NM, was conducted by Food and Drug Investigator Betty Kay Baxter on November 30 to December 1, 1999. That inspection confirmed that you offered animals for sale for slaughter as food, in violation of sections 402(a)(2)(C)(ii) and 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act).

March 10, 1999 USDA analysis of tissue samples collected from your animal (USDA Sample #371781) identified the presence of Oxytetracycline residues of in the muscle, ppm in the kidney, and ppm in the liver. No tolerance has been established for residues of Oxytetracycline in the edible tissues of lactating dairy cattle in Title 21, Code of Federal Regulations, Part 556.500 (21 CFR 556.500). This cow also had Tilmicosin residues of ppm in the muscle. ppm in the kidney, and ppm in the liver. A tolerance for Tilmicosin in liver tissue has been established at 1.2 ppm. No tolerance has been established for residues of Tilmicosin in other edible tissues of cattle (21 CFR 556.735).

Our investigation revealed the probable use of a LA-200 and/or Micotil to treat this cow. The presence of Oxytetracycline and Tilmicosin drugs at the levels found in edible tissues from this animal cause the food to be adulterated within the meaning of section 402(a)(2)(C)(ii) of the Act.

Our investigation also found that you hold animals under conditions which are so inadequate that diseased and/or medicated animals bearing potentially harmful drug residues may enter the food supply. For example, you lack an adequate system for assuring that animals medicated by you or under your direction have been withheld from slaughter for appropriate periods of time to permit depletion of potentially hazardous residues from edible tissues. The food from animals held under such conditions is adulterated within the meaning of section 402(a)(4) of the Act.

It is not necessary for you to personally ship an adulterated animal in interstate commerce to be responsible for a violation of the Act. The fact that you caused the adulteration of an animal that was sold to a slaughterhouse that ships in interstate commerce is sufficient to hold you responsible for a violation of the Act.

The above is not intended as an all-inclusive list of violations. As a livestock auction operator and owner/seller of medicated animals for food use, you are responsible for assuring that your overall operation and the products you distribute are in compliance with the law. You should take prompt action to correct these violations, and you should establish procedures whereby such violations do not recur. Failure to promptly correct these violations may result in regulatory and/or administrative sanctions. These sanctions include, but are not limited to, seizure and/or injunction.

This letter notifies you of our findings and provides you an opportunity to correct the above deficiencies. To avoid future illegal residue violations you should take precautions such as:

- 1) Implement a system to withhold a medicated animal from slaughter for food for an appropriate period of time to deplete potentially hazardous residues of drugs from edible tissue. If you do not want to hold the medicated animal, then it should not be offered for human food, and it should be clearly identified and sold as a medicated animal.
- 2) Implement a system for medical treatment records that include: drug used, treatment period, who administered the drug, amount administered, appropriate withdrawal period and the animal's identification.

You should notify this office in writing within 15 working days of the receipt of this letter, of the steps you have taken to bring your firm into compliance with the law. Your response should include an explanation of each step being taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within 30 working days, state the reason for the delay and the date by which the corrections will be completed. Include copies of any available documentation demonstrating that corrections have been made.

Your response should be directed to Betty Kay Baxter, Acting Compliance Officer, at the above address. If you have questions regarding this letter you may contact Ms. Baxter at (303) 236-3084.

**PURGED** 

Janis V. Halvorsen Acting District Director